Sign in

    John Park

    Partner at Morgan Stanley

    John Park is a Partner at KKR leading the Technology industry team within Americas Private Equity, and before joining KKR in 2013, he held positions at Apax Partners and Morgan Stanley. He has a distinguished track record overseeing investments and board memberships in companies such as Alchemer, Alludo, Barracuda Networks, BMC Software, Cloudera, Internet Brands, mdf commerce, Optiv, and OutSystems, and has been involved with significant investments in ASG Technologies, Epicor, GoDaddy, Mitchell International, Ping Identity, and others. His career began after earning an A.B. from Princeton University and an M.B.A. from Harvard Business School, progressing through key roles in private equity and investment banking before leading technology investments at KKR. Park's professional credentials reflect extensive experience in private equity leadership, although specific FINRA or securities licenses are not detailed in public records.

    John Park's questions to American Well (AMWL) leadership

    John Park's questions to American Well (AMWL) leadership • Q2 2025

    Question

    John Park from Morgan Stanley asked about the gross margin impact of third-party clinical solutions and the value proposition for partners to integrate with Amwell. He also followed up on how macro factors are affecting sales cycles and pricing.

    Answer

    CEO Dr. Ido Schoenberg explained that Amwell's platform reduces customer acquisition costs for partners and simplifies outcomes reporting for sponsors, creating a high-margin revenue stream for Amwell. He noted the current macro focus on cost savings can accelerate sales cycles for solutions that demonstrate clear financial ROI, which is a strength for Amwell's platform.

    Ask Fintool Equity Research AI

    John Park's questions to Doximity (DOCS) leadership

    John Park's questions to Doximity (DOCS) leadership • Q2 2025

    Question

    John Park, on for Craig, asked if management planned to revisit its withdrawn long-term financial targets and what agency partners were saying about the post-election spending environment.

    Answer

    CFO Anna Bryson stated that the company will not issue new long-term targets in the near term, pending more clarity on the pharma digital market growth rate and the full impact of the client portal. CSO Dr. Nate Gross commented that the post-election outlook is still uncertain but that Doximity's platform is relatively insulated. He noted market stability in pharma ETFs suggests significant risk has not been priced in.

    Ask Fintool Equity Research AI